Use of low-dose combined therapy with gemcitabine and paclitaxel for advanced urothelial cancer patients with resistance to cisplatin-containing therapy: a retrospective analysis
Use of low-dose combined therapy with gemcitabine and paclitaxel for advanced urothelial cancer patients with resistance to cisplatin-containing therapy: a retrospective analysis
复制标题
吉西他滨和紫杉醇小剂量联合治疗顺铂耐药的晚期尿路上皮癌患者的回顾性分析
DOI：
--
复制
发表时间：
2012
影响因子：
3
通讯作者：
H. Sakai
中科院分区：
文献类型：
--
作者：
Y. Miyata;Koichiro Nomata;K. Ohba;T. Matsuo;Y. Sagara;H. Kanetake;H. Sakai
目的晚期和复发性尿路上皮癌（UC）患者预后较差。虽然含顺铂（CDDP）的化疗方案是这些患者中最有效的方案，但没有其他确定的化疗方案。我们给予低剂量吉西他滨（GEM）和紫杉醇（PTX）联合治疗，称为低剂量吉西他滨-紫杉醇（lp - gp）治疗，作为这些患者的救助治疗。目的是评估LD-GP治疗对含cddp治疗耐药患者的抗肿瘤作用、疼痛缓解和毒性。患者和方法35例晚期UC患者，先前接受含cddp方案治疗，接受LD-GP治疗（GEM, 700 mg/m2 + PTX, 70 mg/m2，第1天和第8天，每28天重复）。治疗前后用视觉模拟量表测量疼痛。比较了这种治疗方案和其他治疗方案的疼痛缓解和生存率。结果无一例患者对LD-GP治疗完全缓解。25.7%的患者部分缓解，62.9%的患者病情稳定。Kaplan-Meier曲线显示LD-GP治疗患者的生存率高于其他治疗组（p = 0.034）。28例患者（80.0%）疼痛得到充分缓解，只有2例患者需要增加镇痛药。其他方案显示30.4%的患者疼痛缓解。常见的毒性包括白细胞减少，5例患者需要颗粒集落刺激因子治疗（14.3%）。最常见的非血液学毒性是疲劳（n = 7, 17.1%）。结论对含cddp治疗耐药的晚期UC患者，sld - gp治疗是可行且耐受性良好的补救性治疗。
PurposeThe prognosis of patients with advanced and recurrent urothelial cancer (UC) is poor. Although cisplatin (CDDP)-containing chemotherapy is the most effective regimen in these patients, there is no other established chemotherapeutic regimen. We administered combination therapy with low-dose gemcitabine (GEM) and paclitaxel (PTX), named low-dose gemcitabine–paclitaxel (LD-GP) therapy, as salvage therapy for these patients. The aim was to evaluate the anti-tumoral effects, relief of pain, and toxicity of LD-GP therapy in patients with resistance to CDDP-containing therapy.Patients and methodsThirty-five patients with advanced UC, previously treated with CDDP-containing regimens, were treated with LD-GP therapy (GEM, 700 mg/m2 + PTX, 70 mg/m2 on day 1 and 8, repeated every 28 days). Pain was measured on a visual analog scale before and after treatment. Pain relief and survival were compared between this and other treatment regimens.ResultsNone of the patients had complete response to LD-GP therapy. Partial response and stable disease were seen in 25.7 and 62.9 % of patients, respectively. Kaplan–Meier curves showed better survival in patients with LD-GP therapy than with others (p = 0.034). Twenty-eight patients (80.0 %) had adequate pain relief, and only two patients needed to increase their analgesics. Other regimens demonstrated pain relief in 30.4 % of patients. Common toxicities included leukopenia, with five patients requiring granular colony-stimulating factor therapy (14.3 %). The most common non-hematologic toxicity was fatigue (n = 7, 17.1 %).ConclusionsLD-GP therapy is feasible and well tolerated as salvage therapy in patients with advanced UC with resistance to CDDP-containing therapy.
影响因子：
45.3
作者：
Saxman, SB;Propert, KJ;Trump, D
通讯作者：
Trump, D